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6,7], p<0,0001). These associations remained significant after multiple logistic
regression analysis including the severity of the heart defect (univentricular or
biventricular physiology).
Conclusion: Women are more likely to terminate pregnancy if extracar-
diac or chromosomal anomalies are associated. Post natal survival is strongly
influenced by these associated anomalies.
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This study was to review experience and outcomes of supraventricular
(SV) arrhythmias in fetus Methods: Cases were divided in groups: SVPB=
premature SV beats, NSSVT= non-sustained SV tachycardia, SSVT= sus-
tained SV tachycardia, and AF= atrial flutter. Heart failure (HF) was defined
as foetal hydrops or isolated effusion (pericardial or pleural or ascitis). Out-
come was favourable if arrhythmia resolved or stabilized until full-term birth,
not-favourable if premature birth or foetal death occurred. 
Results: 188 fetuses were included:89 in SVPB(47.3%), 31 in
NSSVT(16.5%), 60 in SSVT(31.9%), 8 in AF(4.3%), aged at diagnosis
30.8±4.5weeks (no difference between groups). Foetus HR at diagnosis was
241±30bpm in SSVT vs 226±26 in AF. Antiarrhytmic therapy was adminis-
tered in sustained tachycardia (83% of SSVT and 71% AF): 28 had 1 medica-
tion, 25: 2 medications, 2: 3 medications. Complication occurred in 29 cases,
all in SSVT and AF (29 of 68= 43%): 18 hydrops, 5 ascitis, 4 pericarditis,
1 pleural effusion and 1 LVdysfunction+MR, was more frequent in SSVT
(86%: hydrops in 30%) than AF (51%: no hydrops), p= 0.08. Fetal HF was
associated with HR at diagnosis: 251±25bpm in hydrops vs 228±31bpm in no-
hydrops (p=0.025). Outcome was favourable in SVPB and NSSVT, in 45 of
SSVT+AF (79%). Tachycardia resolved in 36, more frequently in SSVT
(57%) than AF (25%). HR only decreased in 9cases. Premature birth occurred
in 10, foetal death in 2. Outcome was not associated with HR or weeks of ges-
tation at diagnosis. Defavourable outcome was more frequent in hydrops or
isolated effusion (57%) than in uncomplicated cases (10%, p= 0.0002). Reso-
lution occurred in 45% hydrops vs 66% of non-hydrops cases. Digoxine
decreased from 79% of cases before 2000 to 33% after 2000, while flecaine
increased from 14% to 48.5%. There was no relationship between therapy or
number of medications and outcomes. 
Conclusion: Fetal SSVT more frequently resolves but has worse outcome
than AF, especially if HR at diagnosis is high and hydrops occurs. Larger
scale prospective studies are needed to evaluate the efficacy of flecaine com-
pared to digoxine therapy. 
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Risk markers of cardio-vascular events in children with Marfan syndrome
remain little known. Aortic root z-score measurements have been recently
updated. We assessed the prognostic value of aortic root z-score in patients
with Marfan syndrome diagnosed during childhood.
Methods: From the French multicenter database, 457 patients with Marfan
syndrome, diagnosed before 18 y.o., without a history of cardiac event were
prospectively included in this cohort study. Echocardiographic measurements
of aortic root diameters were performed at each visit. We calculated the Z-
score of aortic root measurements using the Bichat formula for each visit.
Mean z-score was defined as the mean of the z-score (MeanZS15) calculated
for each measurement before the age of 16.
Results: Median age at end of FU was 15.9 years (interquartile 10.9-20.3).
FU was complete for 69.5% of patients. Median FU was 4.6 years. A cardio-
vascular event occurred in 17 patients (3.7%, prophylactic aortic surgery
n=14, aortic dissection n=1 and deaths n=2). Survival free of cardiac events
was 85.1% in patients with a meanZS15 of the Valsalva diameter <3 and
56.4% in patients with a meanZS15 of the Valsalva diameter ≥3 (p<0.0001 by
log-rank test).In univariate analysis, Valsalva meanZS15 ≥3, age at inclusion
in the database, a lower heart rate and an increased arm/height ratio were asso-
ciated with an increasing risk of cardiac events (p<0.0001, p=0.04, p=0.01 and
p=0.04 respectively). After multivariate adjustment using a cox proportional
hazards model, only Valsalva meanZS15 ≥3 and lack of FBN1 or TGBB
mutation identified were associated with an increasing risk of cardiac events
(p<0.0001 and p=0.04 respectively).
Conclusion: Valsalva meanZS15 may help to predict whose children with
a Marfan syndrome will have a cardio-vascular event. Therefore a particular
attention to beta-blockade treatment observance and a regular follow-up may
be suggested in high-risk children. 
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Objectives: Left ventricular ejection causes a forward flow in the fetal
aortic isthmus while right ventricle (RV) has a retrograde influence. The
objective of this study was to test the hypothesis that non restrictive ventric-
ular septal defects (VSD) could cancel out the normal fetal RV preponderance
and its retrograde systolic effect on the isthmic flow pattern.
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